Jaguar Health Restructures Debt and Royalty Obligations

Company aims to strengthen balance sheet and focus on rare disease drug development.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Jaguar Health, a San Francisco-based pharmaceutical company, has announced a restructuring of its debt and royalty obligations in an effort to strengthen its balance sheet. The company says this will allow it to continue its strategic focus on the global development program for its lead drug candidate, crofelemer, for rare disease intestinal failure indications.

Why it matters

Jaguar Health's ability to manage its financial obligations is crucial for the company to maintain operations and fund its drug development pipeline, particularly for rare disease treatments which often require significant investment. Strengthening the company's balance sheet could improve its financial flexibility and long-term viability.

The details

As part of the restructuring, Jaguar Health has renegotiated its debt and royalty agreements to reduce its financial obligations. The company says this will help it to better allocate resources towards its strategic priorities, including the global development program for crofelemer.

  • Jaguar Health announced the debt and royalty restructuring on March 9, 2026.

The players

Jaguar Health

A San Francisco-based pharmaceutical company focused on developing treatments for rare diseases.

Got photos? Submit your photos here. ›

What’s next

Jaguar Health says it will continue to explore additional opportunities to further restructure and reduce its debt obligations in the coming months.

The takeaway

Jaguar Health's debt restructuring demonstrates the company's commitment to strengthening its financial position and focusing its resources on the development of its rare disease drug pipeline, which could have significant implications for patients in need of new treatment options.